A narrative review published in the Cureus Journal of Medical Science has examined how researchers assess probiotic effects on the gut microbiome, highlighting that faecal sampling, the most common method used in microbiome studies, may not fully capture what is happening at the gut lining. The review notes that mucosal microbiota samples have proven more effective than stool samples at distinguishing between subtypes of inflammatory bowel disease (IBD).
Faecal samples are widely used in gut microbiome research because they are non-invasive, inexpensive, and easy to collect repeatedly over time. This makes them the default choice for tracking how probiotics or dietary interventions might shift the balance of gut bacteria. However, the gut microbiome is not uniform throughout the digestive tract: the community of microbes living in close contact with the intestinal lining, known as the mucosal microbiota, differs meaningfully from the microbes found in stool, which largely reflect what is transiting through the gut lumen. For conditions such as Crohn’s disease and ulcerative colitis, where inflammation originates at or near the mucosal surface, this distinction matters.
According to the review’s authors, studies specifically looking at IBD found that mucosal microbiota samples were more effective than faecal samples at distinguishing between disease subtypes. This suggests that stool-based testing, while convenient, may miss microbial signatures that are specific to the site of inflammation and that could otherwise help differentiate between conditions such as Crohn’s disease and ulcerative colitis, or between active and quiescent disease. The authors present this as part of a broader discussion of methodological considerations when using faecal sampling to evaluate probiotic interventions, arguing that researchers need to weigh the practicality of stool collection against its capacity to reflect biologically relevant changes occurring closer to the gut wall.
For clinicians and researchers working in IBD, this distinction has practical implications for how microbiome research should be interpreted. Trials that rely solely on faecal sampling to demonstrate that a probiotic or dietary therapy has altered the gut microbiome may be underestimating, or missing entirely, changes occurring at the mucosal surface where inflammation actually develops. This does not mean faecal sampling is without value, but it does suggest a degree of caution is warranted when drawing conclusions about disease-specific microbial changes from stool data alone. The review’s observations are relevant to how future studies in IBD and gastrointestinal nutrition are designed, particularly where mucosal biopsy sampling, though more invasive, may offer a more accurate picture of microbial activity at the site of disease.
Reference
Use of fecal sampling for assessing probiotic effects on the gut microbiome: a focused narrative review. Cureus Journal of Medical Science. Full author list, volume, page range and DOI were not available in the source material supplied and have therefore been omitted rather than invented. Readers are directed to the original article on the Cureus platform for complete citation details.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.